However, the results of other trials investigating checkpoint inhibitors in HNSCC were inconsistent and it is therefore still unclear which PD-L1 cut-off and detection method serve best as a biomarker in HNSCC. Here, CD274 is linked to head and neck squamous cell carcinoma.